• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤大小对膀胱Ta/T1期癌复发和进展的影响。

Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder.

作者信息

Jancke Georg, Rosell Johan, Jahnson Staffan

机构信息

Department of Urology, University Hospital, Linköping, Sweden.

出版信息

Scand J Urol Nephrol. 2011 Dec;45(6):388-92. doi: 10.3109/00365599.2011.590995. Epub 2011 Jun 16.

DOI:10.3109/00365599.2011.590995
PMID:21679018
Abstract

OBJECTIVE

This study aimed to evaluate the impact of tumour size on recurrence and progression in a population-based series of non-muscle-invasive bladder cancers.

MATERIAL AND METHODS

Clinical and pathological characteristics of patients with primary Ta/T1 bladder cancer were registered. The patients' tumours were categorized by size into five size groups (1-10, 11-20, 21-30, 31-40 and >40 mm) or three size groups (1-15, 16-30 and >30 mm).

RESULTS

The analysis included 768 evaluable patients with a mean follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Tumour size was associated with recurrence for tumours sized 21?30, 31?40 and >40 mm (p = 0.03, p < 0.001, p < 0.001, respectively) in the five size group and for tumours sized 16?30 and >30 mm (p = 0.003 and p < 0.001) in the three size group. Other factors affecting recurrence were T1 tumour category, multiplicity and surgery performed by residents (p < 0.001, p < 0.001, p = 0.002, respectively). Considering progression, there was no significant association with tumour size, and T1 category and local recurrence were the only significant risk factors (both p < 0.001).

CONCLUSION

Tumour size ?15 mm is associated with a lower risk of recurrence but not progression. Dividing tumour size into three size groups gives additional information compared with two size groups with cut-off at 30 mm.

摘要

目的

本研究旨在评估在一项基于人群的非肌层浸润性膀胱癌系列研究中肿瘤大小对复发和进展的影响。

材料与方法

记录原发性Ta/T1期膀胱癌患者的临床和病理特征。根据肿瘤大小将患者的肿瘤分为五个大小组(1 - 10、11 - 20、21 - 30、31 - 40和>40 mm)或三个大小组(1 - 15、16 - 30和>30 mm)。

结果

分析纳入了768例可评估患者,平均随访60个月。478例患者(62%)出现复发,71例(9%)出现进展。在五个大小组中,肿瘤大小为21 - 30、31 - 40和>40 mm的肿瘤与复发相关(分别为p = 0.03、p < 0.001、p < 0.001),在三个大小组中,肿瘤大小为16 - 30和>30 mm的肿瘤与复发相关(p = 0.003和p < 0.001)。影响复发的其他因素是T1肿瘤类别、肿瘤多发以及住院医师进行的手术(分别为p < 0.001、p < 0.001、p = 0.002)。考虑进展情况,肿瘤大小与之无显著关联,T1类别和局部复发是仅有的显著危险因素(均为p < 0.001)。

结论

肿瘤大小≤15 mm与较低的复发风险相关,但与进展无关。与以30 mm为界的两个大小组相比,将肿瘤大小分为三个大小组可提供更多信息。

相似文献

1
Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder.肿瘤大小对膀胱Ta/T1期癌复发和进展的影响。
Scand J Urol Nephrol. 2011 Dec;45(6):388-92. doi: 10.3109/00365599.2011.590995. Epub 2011 Jun 16.
2
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果:日本泌尿外科学会1999 - 2001年报告
Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.
3
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.女性性别和前列腺尿道原位癌是 T1G3 膀胱癌患者接受卡介苗治疗后复发、进展和疾病特异性死亡率的预后因素。
Eur Urol. 2012 Jul;62(1):118-25. doi: 10.1016/j.eururo.2011.10.029. Epub 2011 Oct 25.
4
Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence.原发性Ta/T1期膀胱癌中肿瘤位置邻近输尿管口可预测复发。
Scand J Urol. 2016;50(1):33-8. doi: 10.3109/21681805.2015.1066849. Epub 2015 Jul 23.
5
Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.pTa/pT1期膀胱癌患者局部复发的危险因素。
Scand J Urol Nephrol. 2008;42(5):417-21. doi: 10.1080/00365590802016302.
6
Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.卡介苗治疗Ta/T1期膀胱癌:复发和进展时间的预后因素
BJU Int. 2004 May;93(7):980-4. doi: 10.1111/j.1464-410X.2003.04764.x.
7
The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.性别对卡介苗治疗非肌肉浸润性膀胱癌患者的疗效的影响。
BJU Int. 2010 Aug;106(3):357-61. doi: 10.1111/j.1464-410X.2009.09137.x. Epub 2009 Dec 11.
8
Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.瑞典非肌层浸润性膀胱癌的局部复发与进展:一项基于人群的随访研究
Scand J Urol. 2015;49(4):290-5. doi: 10.3109/21681805.2014.1000963. Epub 2015 Jan 26.
9
Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.一项比较卡介苗和表柔比星作为浅表性膀胱癌辅助治疗的随机前瞻性试验的12年随访
Int J Urol. 2005 May;12(5):449-55. doi: 10.1111/j.1442-2042.2005.01064.x.
10
Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?卡介苗治疗后无肿瘤患者,五年后是否需要继续进行膀胱镜随访?
Eur Urol. 2012 Mar;61(3):503-7. doi: 10.1016/j.eururo.2011.11.011. Epub 2011 Nov 15.

引用本文的文献

1
Efficacy and safety of office-based diode laser ablation for recurrent low-grade non-muscle-invasive bladder cancer under local anaesthesia: A pilot study.局部麻醉下门诊二极管激光消融治疗复发性低级别非肌层浸润性膀胱癌的疗效及安全性:一项前瞻性研究。
Arab J Urol. 2024 Jul 18;23(1):70-74. doi: 10.1080/20905998.2024.2381816. eCollection 2025.
2
The Influence of Inverted Growth Pattern on Recurrence for Patients with Non-Invasive Low Grade Papillary Urothelial Carcinoma of Bladder.倒置生长模式对膀胱低级别非浸润性乳头状尿路上皮癌患者复发的影响。
Balkan Med J. 2017 Sep 29;34(5):464-468. doi: 10.4274/balkanmedj.2017.0081. Epub 2017 Apr 13.
3
Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease.
卡介苗(BCG)治疗非肌层浸润性膀胱癌失败:真正构成无反应疾病的因素是什么。
Bladder Cancer. 2015 Oct 26;1(2):105-116. doi: 10.3233/BLC-150015.
4
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study.经尿道膀胱肿瘤切除术后静脉化疗联合膀胱灌注化疗治疗T1G3膀胱尿路上皮癌:一项回顾性研究结果
Onco Targets Ther. 2016 Jan 28;9:605-11. doi: 10.2147/OTT.S99866. eCollection 2016.
5
Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.影响经膀胱内卡介苗治疗的高级别非浸润性膀胱癌复发和进展的因素。
Pak J Med Sci. 2014 Mar;30(2):326-30. doi: 10.12669/pjms.302.4117.